机构:[1]Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing, China,泌尿外科首都医科大学宣武医院[2]Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, United States,[3]Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States,[4]Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC, United States
Toll-like receptor (TLR) 4 is expressed on normal and malignant prostate epithelial cells. The TLR4 and its downstream signaling pathways mediate innate immune responses in the host against invading pathogens. However, multiple lines of evidence shows that TLR4 expression is increased in prostate tissues from prostate cancer patients, and altered TLR4 signals may promote cancer development, as well as antitumor effects. In this review, we have summarized key features of the TLR4 signaling pathway and its associated immune responses and focused on the pathologic role of TLR4 in prostate carcinogenesis and tumor progression.
基金:
the National Institute of Allergy and Infectious Diseases grant AI091526 and AI1288864 ,
the DOD/CDMRP Prostate Cancer Research Program grant W81XWH-15-1-0696,
American Cancer Society Institutional Research Grant awarded to the Hollings Cancer Center, Medical University of South Carolina.
第一作者机构:[1]Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing, China,
通讯作者:
通讯机构:[1]Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing, China,
推荐引用方式(GB/T 7714):
Tongwen Ou,Michael Lilly,Wei Jiang.The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer[J].FRONTIERS IN IMMUNOLOGY.2018,9(JUN):1188.doi:10.3389/fimmu.2018.01188.
APA:
Tongwen Ou,Michael Lilly&Wei Jiang.(2018).The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.FRONTIERS IN IMMUNOLOGY,9,(JUN)
MLA:
Tongwen Ou,et al."The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer".FRONTIERS IN IMMUNOLOGY 9..JUN(2018):1188